Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Joshua R. Rosenberg"'
Autor:
Sarah C. J. Jorgensen, Trang D. Trinh, Evan J. Zasowski, Abdalhamid M. Lagnf, Sahil Bhatia, Sarah M. Melvin, Samuel P. Simon, Joshua R. Rosenberg, Molly E. Steed, Sandra J. Estrada, Taylor Morrisette, Susan L. Davis, Michael J. Rybak
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 2, Pp 291-304 (2020)
Abstract Background The aim of this study was to evaluate the predictive performance of the INCREMENT-CPE (ICS), Pitt bacteremia score (PBS) and qPitt for mortality among patients treated with ceftazidime–avibactam for carbapenem-resistant Enteroba
Externí odkaz:
https://doaj.org/article/a418b4cd99f0401695ee735da7bc77bf
Publikováno v:
Open Forum Infectious Diseases
Background Eravacycline (ERV) is FDA-approved for the treatment of complicated intra-abdominal infections, but there is limited experience for non-FDA approved indications. Methods We present five cases that utilized ERV for treatment of bacteremia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0bdea2269f149042d0f674a1aef1e8c
http://europepmc.org/articles/PMC8644661
http://europepmc.org/articles/PMC8644661
Autor:
Susan L. Davis, Natalie A. Finch, Molly E. Steed, Taylor Morrisette, Evan J Zasowski, Sarah M Melvin, Sarah C J Jorgensen, Trang D Trinh, Samuel Simon, Joshua R Rosenberg, Sahil Bhatia, Sandy Estrada, Abdalhamid M Lagnf, Michael J. Rybak
Publikováno v:
Antimicrob Agents Chemother
Our objective was to describe the prescribing practices, clinical characteristics, and outcomes of patients treated with ceftolozane-tazobactam (C/T) for multidrug-resistant (MDR) Gram-negative infections. This was a multicenter, retrospective, cohor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb1e667e65fbf8881dbc66fadd02c44d
https://doi.org/10.1128/aac.02291-19
https://doi.org/10.1128/aac.02291-19
Autor:
Samuel Simon, Sahil Bhatia, Taylor Morrisette, Joshua R Rosenberg, Abdalhamid M Lagnf, Michael J. Rybak, Sarah M Melvin, Trang D Trinh, Kimberly C. Claeys, Sandra J Estrada, Molly E. Steed, Evan J Zasowski, Susan L. Davis, Sarah C J Jorgensen
Publikováno v:
Open Forum Infectious Diseases
Background We conducted this study to describe the clinical characteristics, microbiology, and outcomes of patients treated with ceftazidime-avibactam (CZA) for a range of multidrug-resistant Gram-negative (MDR-GN) infections. Methods This is a multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8dc82b1ac816d6783ab07de6d337fff
https://pubmed.ncbi.nlm.nih.gov/31890725
https://pubmed.ncbi.nlm.nih.gov/31890725
Autor:
Susan L. Davis, Sandra J Estrada, Sara Alosaimy, Sarah C J Jorgensen, Evan J Zasowski, Sahil Bhatia, Abdalhamid M Lagnf, Trang D Trinh, Molly E. Steed, Michael J. Rybak, Joshua R Rosenberg, Samuel Simon, Sarah Melvin
Publikováno v:
Open Forum Infectious Diseases
Background Ceftazidime–avibactam (CZA) is a novel cephalosporin/β-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae (CRE) and multidrug-resistant (MDR) Pseudomonas aeruginosa (PA). Real-world experience with CZA for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b07c3d62bc9a45d50b7fad31dd62c685
http://europepmc.org/articles/PMC6809679
http://europepmc.org/articles/PMC6809679
Autor:
Sarah C J Jorgensen, Joshua R Rosenberg, Trang D Trinh, Sahil Bhatia, Evan J Zasowski, Sandy Estrada, Susan L. Davis, Abdalhamid M Lagnf, Michael J. Rybak, Samuel Simon, Molly E. Steed
Publikováno v:
Open Forum Infectious Diseases
Background Delayed appropriate antibiotic therapy for multidrug-resistant (MDR) Gram-negative bacterial (GNB) infections has been associated with increased mortality. Ceftolozane-tazobactam (C/T) is a novel antipseudomonal cephalosporin and β-lactam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3a4f3942c520f6266f96a3dcfbc90a1
http://europepmc.org/articles/PMC6253708
http://europepmc.org/articles/PMC6253708
Autor:
Sandy Estrada, Abdalhamid M Lagnf, Trang D Trinh, Sarah C J Jorgensen, Michael J. Rybak, Sahil Bhatia, Evan J Zasowski, Joshua R Rosenberg, Samuel Simon, Susan L. Davis, Molly E. Steed
Publikováno v:
Open Forum Infectious Diseases
Background The increasing prevalence of multidrug-resistant (MDR) Gram-negative bacteria (GNB) represents an urgent public health threat. Ceftazidime–avibactam (CZA) is a novel cephalosporin/β-lactamase inhibitor with activity against MDR GNB incl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b24cd235fb44a933625bbc9534f1baa
http://europepmc.org/articles/PMC6255400
http://europepmc.org/articles/PMC6255400